spinocerebellar ataxia

Reading File
Finding Sources
Searching PubMed

"spinocerebellar ataxia"[MeSH Terms]

Searching Images

spinocerebellar ataxia MRI cerebellum atrophy

This diagnostic imaging panel presents a series of brain MRI scans illustrating progressive cerebellar atrophy in Spinocerebellar Ataxia Type 13 (SCA13). The primary images are T1-weighted midline sagittal sections (a-f), accompanied by T2-weighted axial insets (a, d, e, f). The sagittal views demonstrate varying degrees of cerebellar vermis shrinkage and enlargement of the pericerebellar CSF spaces. Notably, while the cerebellum shows marked volume loss particularly in long-duration cases (d and f), the brainstem and pons appear relatively preserved. The axial insets highlight widening of the cerebellar fissures and thinning of the folia, characteristic of global cerebellar atrophy. Serial scans for two patients (b to e; c to f) taken over a 5-year interval show subtle radiographic progression despite clinically significant increases in Scale for Assessment and Rating of Ataxia (SARA) scores. The images correlate disease duration (dd) and clinical severity (ss) with structural neuroanatomical changes, serving as an educational resource for identifying isolated cerebellar neurodegeneration.

This diagnostic imaging panel presents a series of brain MRI scans illustrating progressive cerebellar atrophy in Spinocerebellar Ataxia Type 13 (SCA13). The primary images are T1-weighted midline sagittal sections (a-f), accompanied by T2-weighted axial insets (a, d, e, f). The sagittal views demonstrate varying degrees of cerebellar vermis shrinkage and enlargement of the pericerebellar CSF spaces. Notably, while the cerebellum shows marked volume loss particularly in long-duration cases (d and f), the brainstem and pons appear relatively preserved. The axial insets highlight widening of the cerebellar fissures and thinning of the folia, characteristic of global cerebellar atrophy. Serial scans for two patients (b to e; c to f) taken over a 5-year interval show subtle radiographic progression despite clinically significant increases in Scale for Assessment and Rating of Ataxia (SARA) scores. The images correlate disease duration (dd) and clinical severity (ss) with structural neuroanatomical changes, serving as an educational resource for identifying isolated cerebellar neurodegeneration.

This diagnostic image set features T1-weighted MRI scans of the cerebellum and brainstem from eleven patients with Spinocerebellar Ataxia type 2 (SCA2), labeled CB1 through CB12 (excluding CB11). The scans are presented in representative axial (z-plane) and coronal (y-plane) sections, all normalized to the Spatially Unbiased Infratentorial Template (SUIT) shown in the bottom right for comparison. The educational focus is on the spectrum of cerebellar atrophy characteristic of SCA2. Morphological changes across the patient cohort include a significant reduction in cerebellar volume, narrowing of the cerebellar folia, and prominent widening of the cerebellar sulci and fissures compared to the healthy template. Specific variations are visible in the cerebellar vermis and hemispheres, ranging from mild volume loss to severe shrinkage (e.g., CB6 and CB10). These neuroimaging findings demonstrate the progressive neurodegenerative effects on the posterior fossa structures, which are essential for diagnosing and monitoring the clinical severity of autosomal dominant ataxias.

This diagnostic image set features T1-weighted MRI scans of the cerebellum and brainstem from eleven patients with Spinocerebellar Ataxia type 2 (SCA2), labeled CB1 through CB12 (excluding CB11). The scans are presented in representative axial (z-plane) and coronal (y-plane) sections, all normalized to the Spatially Unbiased Infratentorial Template (SUIT) shown in the bottom right for comparison. The educational focus is on the spectrum of cerebellar atrophy characteristic of SCA2. Morphological changes across the patient cohort include a significant reduction in cerebellar volume, narrowing of the cerebellar folia, and prominent widening of the cerebellar sulci and fissures compared to the healthy template. Specific variations are visible in the cerebellar vermis and hemispheres, ranging from mild volume loss to severe shrinkage (e.g., CB6 and CB10). These neuroimaging findings demonstrate the progressive neurodegenerative effects on the posterior fossa structures, which are essential for diagnosing and monitoring the clinical severity of autosomal dominant ataxias.

This diagnostic imaging panel presents a multi-planar MRI series of the brain for two separate individuals diagnosed with Spinocerebellar Ataxia Type 5 (SCA5). The top row (a–c) displays the proband, while the bottom row (d–f) displays a sporadic patient. The modalities include sagittal T1-weighted images (a, d), coronal T2-weighted images (b, e), and axial T1-weighted images (c, f). The primary clinical finding across both patients is moderate cerebellar atrophy. In the sagittal views, there is noticeable widening of the cerebellar fissures and a reduction in the volume of the cerebellar vermis. The coronal T2-weighted images highlight prominent cerebellar folia and enlarged CSF spaces surrounding the cerebellum, indicative of parenchymal loss. Despite the cerebellar changes, the supratentorial structures, including the cerebral cortex and ventricular system, appear largely preserved with normal ventricular size. This pattern is characteristic of pure cerebellar ataxia syndromes where atrophy is predominantly isolated to the infratentorial compartment, specifically the cerebellum and brainstem.

This diagnostic imaging panel presents a multi-planar MRI series of the brain for two separate individuals diagnosed with Spinocerebellar Ataxia Type 5 (SCA5). The top row (a–c) displays the proband, while the bottom row (d–f) displays a sporadic patient. The modalities include sagittal T1-weighted images (a, d), coronal T2-weighted images (b, e), and axial T1-weighted images (c, f). The primary clinical finding across both patients is moderate cerebellar atrophy. In the sagittal views, there is noticeable widening of the cerebellar fissures and a reduction in the volume of the cerebellar vermis. The coronal T2-weighted images highlight prominent cerebellar folia and enlarged CSF spaces surrounding the cerebellum, indicative of parenchymal loss. Despite the cerebellar changes, the supratentorial structures, including the cerebral cortex and ventricular system, appear largely preserved with normal ventricular size. This pattern is characteristic of pure cerebellar ataxia syndromes where atrophy is predominantly isolated to the infratentorial compartment, specifically the cerebellum and brainstem.

Diagnostic neuroimaging (MRI) of the brain in T1-weighted sequences, presenting a sagittal view (A) and an axial view (B). The images demonstrate significant olivopontocerebellar atrophy in a patient with Spinocerebellar Ataxia Type 2 (SCA2). In the sagittal view, there is marked volume loss of the cerebellum and the brainstem (specifically the pons and medulla), characterized by prominent cerebellar fissures and a diminished pontine belly. The axial view confirms these findings, showing disproportionate cerebellar atrophy relative to the cerebral hemispheres, with widening of the cerebellar sulci and thinning of the folia. These radiological features are consistent with the clinical presentation of progressive ataxia, dysarthria, and slowed saccadic eye movements. The images serve as an educational example of neurodegeneration in Autosomal Dominant Cerebellar Ataxia (ADCA), highlighting the anatomical distribution of tissue loss in the posterior fossa.

Diagnostic neuroimaging (MRI) of the brain in T1-weighted sequences, presenting a sagittal view (A) and an axial view (B). The images demonstrate significant olivopontocerebellar atrophy in a patient with Spinocerebellar Ataxia Type 2 (SCA2). In the sagittal view, there is marked volume loss of the cerebellum and the brainstem (specifically the pons and medulla), characterized by prominent cerebellar fissures and a diminished pontine belly. The axial view confirms these findings, showing disproportionate cerebellar atrophy relative to the cerebral hemispheres, with widening of the cerebellar sulci and thinning of the folia. These radiological features are consistent with the clinical presentation of progressive ataxia, dysarthria, and slowed saccadic eye movements. The images serve as an educational example of neurodegeneration in Autosomal Dominant Cerebellar Ataxia (ADCA), highlighting the anatomical distribution of tissue loss in the posterior fossa.

Reading File
Reading File
Searching PubMed

"spinocerebellar ataxia" AND treatment

Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the full answer.

Spinocerebellar Ataxia (SCA)

Overview

Spinocerebellar ataxias (SCAs) are a large group of autosomal dominant, progressive, adult-onset neurodegenerative disorders characterized by cerebellar ataxia with variable extracerebellar manifestations. They affect the cerebellum and its afferent/efferent pathways. The genetic nomenclature numbers them in order of locus discovery - the count has now reached SCA 48 and beyond.
  • Collective prevalence: 1.0-5.6 per 100,000 - all are rare by US government definition
  • SCA3 (Machado-Joseph disease) is the most common SCA worldwide
  • Bradley and Daroff's Neurology in Clinical Practice

Genetic Classification and Mutations

Mutation TypeSCAs InvolvedMechanism
CAG trinucleotide repeat (polyQ expansion)SCA 1, 2, 3, 6, 7, 17; DRPLAToxic gain of function by mutant polyQ protein
CTG repeat (3'UTR of ATXN8OS)SCA8Toxic untranslated RNA
Intronic pentanucleotide repeatSCA10, SCA31, SCA37Toxic untranslated RNA
Hexanucleotide repeat expansionSCA36Toxic RNA
Missense mutationsMost other SCAsToxic gain of function or dominant negative effect
DeletionsSCA15/16, SCA14Haploinsufficiency
DuplicationsSCA20-
TranslocationSCA27Haploinsufficiency
These mechanistic distinctions matter for therapy: repeat expansions and missense mutations are good targets for RNA silencing therapy, while haploinsufficiency disorders require gene replacement therapy or transcription enhancers.
  • Bradley and Daroff's Neurology in Clinical Practice

Regional and Ethnic Distribution

RegionPredominant SCA
US & EuropeSCA1, 2, 3, 6, 7, 8
PolandSCA1 (high frequency, founder effect)
Cuba, Mexico, ItalySCA2
UK, Germany, JapanSCA6
South Africa, Mexico, VenezuelaSCA7
Latin AmericaSCA10
India, ItalySCA12
SCA prevalence by country showing distribution of SCA subtypes

Clinical Classification (Harding's ADCA Types)

ADCA I - Cerebellar ataxia plus variable extracerebellar CNS signs
  • SCA2: slow saccades
  • SCA3: dystonia
  • SCA1, SCA17, and others
ADCA II - Cerebellar ataxia plus pigmentary macular degeneration
  • SCA7 (the only known ADCA II)
ADCA III - Nearly pure cerebellar ataxia
  • SCA6 (most typical)

Core Clinical Features

Universal to most SCAs:
  • Progressive gait ataxia and balance loss (typically the onset symptom)
  • Limb dysmetria
  • Dysarthria (scanning or explosive speech)
  • Nystagmus and oculomotor abnormalities
SCA-specific distinguishing features:
SCA TypeDistinctive Features
SCA1Pyramidal signs, peripheral neuropathy, ophthalmoplegia
SCA2Slow saccades (highly characteristic), hyporeflexia, parkinsonism (may be L-DOPA responsive); long ATXN2 alleles are an ALS risk factor
SCA3 (MJD)Spasticity, cramps, fasciculations of face/tongue, protuberant eyes, external ophthalmoparesis, dystonia, rigidity; onset 3rd-7th decade
SCA6Pure cerebellar, late onset, very mild progression, no anticipation
SCA7Pigmentary retinal degeneration - progressive visual loss alongside ataxia
SCA10Seizures (especially in Latin American patients)
SCA17Dementia, psychiatric features, parkinsonism (resembles Huntington disease)
Cognitive involvement: Cerebellar Cognitive Affective Syndrome (CCAS/Schmahmann Syndrome) - underrecognized cognitive impairments - may occur across multiple SCA subtypes.
  • Bradley and Daroff's Neurology in Clinical Practice

Genetic Anticipation

Progressively earlier onset in successive generations with increasing severity - a hallmark of most polyQ SCAs. This is caused by intergenerational instability and expansion of the CAG repeat number.
  • Explains de novo cases and juvenile-onset presentations
  • SCA6 lacks anticipation (small, stable CAG repeats)
  • SCA17 partially lacks anticipation (CAA interruptions within the expanded CAG)

Pathogenic Mechanisms

PolyQ SCAs: Toxic gain of function by the mutant polyglutamine-containing protein. The expanded polyQ tract causes protein misfolding, aggregation into intranuclear neuronal inclusion bodies, and interference with cellular proteasome function (well-studied in SCA3/MJD).
Repeat expansion SCAs (intronic): Toxic untranslated RNA containing large expanded repeats.
Non-polyQ SCAs: Haploinsufficiency or dominant negative effects depending on the specific mutation type.

Neuroimaging

MRI shows characteristic findings:
  • Cerebellar atrophy - widening of cerebellar fissures, thinning of folia, reduced vermis volume
  • Olivopontocerebellar atrophy - especially in SCA2, with marked volume loss of pons and medulla alongside cerebellum
  • Cerebellar atrophy tends to be isolated (supratentorial structures relatively preserved) in "pure" cerebellar subtypes like SCA6
Serial MRI shows progressive volume loss correlated with clinical severity scores (SARA - Scale for Assessment and Rating of Ataxia).
SCA2 MRI showing olivopontocerebellar atrophy
SCA2: marked cerebellar + brainstem (pontine) volume loss on T1-weighted MRI
SCA13 progressive cerebellar atrophy on serial MRI
SCA13: serial sagittal T1 MRI over 5 years showing progressive cerebellar vermis shrinkage
  • Grainger & Allison's Diagnostic Radiology

Diagnosis

  1. Clinical evaluation - phenotype, family history, ethnic background, anticipation pattern
  2. Genetic testing - targeted repeat-expansion PCR for common SCAs (SCA1, 2, 3, 6, 7, 8, 10, 12, 17, etc.)
  3. MRI brain - cerebellar atrophy pattern
  4. Electrophysiology - nerve conduction studies for associated neuropathy
Genetic counseling is always recommended before and after testing. Presymptomatic testing follows guidelines similar to Huntington disease (National Ataxia Foundation guidelines). Preimplantation genetic diagnosis (PGD) is technically feasible.

Management

There is currently no disease-modifying therapy approved for any SCA. Management is symptomatic and supportive:
Pharmacological (symptomatic):
  • Tremor/ataxia: Acetazolamide (especially SCA6), 4-aminopyridine (reduces downbeat nystagmus and ataxia in SCA6)
  • Spasticity: Baclofen, tizanidine
  • Dystonia: Botulinum toxin, anticholinergics
  • Parkinsonism (SCA2): L-DOPA may help in some cases
Non-pharmacological:
  • Physiotherapy and balance training
  • Speech therapy for dysarthria
  • Occupational therapy
  • Mobility aids, fall prevention
Emerging therapies (investigational):
  • RNA silencing (ASO/siRNA) - targeting toxic gain-of-function mutations (especially SCA1, 2, 3)
  • Gene replacement therapy - for haploinsufficiency subtypes
  • Small molecule chaperones and proteasome modulators

Key Points Summary

FeatureDetail
InheritanceAutosomal dominant (most common)
PathogenesisPolyglutamine toxicity (most), toxic RNA (some), haploinsufficiency (rare)
Most common worldwideSCA3 (Machado-Joseph Disease)
Hallmark of polyQ SCAsGenetic anticipation
Only ADCA IISCA7 (retinal degeneration)
Distinguishing feature SCA2Slow saccades
Distinguishing feature SCA6Pure cerebellar, no anticipation, acetazolamide-responsive
TreatmentNo disease-modifying therapy; symptomatic only
ImagingCerebellar (± brainstem) atrophy on MRI
This is a shared conversation. Sign in to Orris to start your own chat.